A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies

Lydia Usha; Michael W. Sill; Kathleen M. Darcy; Doris M. Benbrook; Jean A. Hurteau; David P. Michelin; Robert S. Mannel; Parviz Hanjani; Koen De Geest; Andrew K. Godwin

doi:10.1016/j.ygyno.2011.02.013

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.02.013 ◽

2011 ◽

Vol 121 (3) ◽

pp. 455-461 ◽

Cited By ~ 33

Author(s):

Lydia Usha ◽

Michael W. Sill ◽

Kathleen M. Darcy ◽

Doris M. Benbrook ◽

Jean A. Hurteau ◽

...

Keyword(s):

Protein Kinase C ◽

Protein Kinase ◽

Phase Ii ◽

Prognostic Value ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Kinase C ◽

Predictive And Prognostic Value

Get full-text (via PubEx)

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.07.127 ◽

2012 ◽

Vol 127 (2) ◽

pp. 345-350 ◽

Cited By ~ 69

Author(s):

Kimberly K. Leslie ◽

Michael W. Sill ◽

Heather A. Lankes ◽

Edgar G. Fischer ◽

Andrew K. Godwin ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Prognostic Value ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Egfr Mutations ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Recurrent Endometrial Cancer

Get full-text (via PubEx)

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70331-2 ◽

2007 ◽

Vol 2007 ◽

pp. 82-83

Author(s):

J.T. Thigpen

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

Faculty Opinions recommendation of Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969752.793471344 ◽

2013 ◽

Author(s):

David Kushner ◽

Ryan Spencer

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (A Gynecologic Oncology Group Study)

American Journal of Obstetrics and Gynecology ◽

10.1016/0002-9378(89)90507-3 ◽

1989 ◽

Vol 161 (2) ◽

pp. 309-312 ◽

Cited By ~ 110

Author(s):

Gregory P. Sutton ◽

John A. Blessing ◽

Neil Rosenshein ◽

Guy Photopulos ◽

Philip J. DiSaia

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.055 ◽

2015 ◽

Vol 137 ◽

pp. 24 ◽

Cited By ~ 2

Author(s):

K.N. Moore ◽

M. Sill ◽

M.E. Tenney ◽

C.J. Darus ◽

D. Griffin ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Recurrent Carcinoma ◽

Amg 386 ◽

Angiopoietin 1

Get full-text (via PubEx)

A phase II trial of didemnin B (NSC No. 325319) in advanced and recurrent cervical carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/0090-8258(92)90055-n ◽

1992 ◽

Vol 44 (3) ◽

pp. 268-270 ◽

Cited By ~ 11

Author(s):

Allan J. Jacobs ◽

John A. Blessing ◽

Alan Munoz

Keyword(s):

Cervical Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Didemnin B ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2003.11.023 ◽

2004 ◽

Vol 92 (2) ◽

pp. 644-647 ◽

Cited By ~ 117

Author(s):

Katherine Y Look ◽

Alan Sandler ◽

John A Blessing ◽

Joseph A Lucci ◽

Peter G Rose

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Uterine Leiomyosarcoma ◽

Gynecologic Oncology Group ◽

Second Line ◽

Oncology Group ◽

Second Line Chemotherapy ◽

Line Chemotherapy

Get full-text (via PubEx)

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79511-7 ◽

2010 ◽

Vol 2010 ◽

pp. 73-74

Author(s):

J.T. Thigpen

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Her2 Positive ◽

Oncology Group Study

Get full-text (via PubEx)

Phase II trial of liposomal doxorubicin at 40 mg/m2 every 4 weeks in endometrial carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.05.016 ◽

2005 ◽

Vol 98 (2) ◽

pp. 294-298 ◽

Cited By ~ 27

Author(s):

Howard D. Homesley ◽

John A. Blessing ◽

Joel Sorosky ◽

Gary Reid ◽

Katherine Y. Look

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary A Gynecologic Oncology Group study

American Journal of Clinical Oncology ◽

10.1097/00000421-198406000-00012 ◽

1984 ◽

Vol 7 (3) ◽

pp. 261-264 ◽

Cited By ~ 1

Author(s):

J. Tate Thigpen ◽

John A. Blessing ◽

James C. Arseneau ◽

Howard D. Homesley

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Recurrent Carcinoma ◽

Carcinoma Of The Ovary

Get full-text (via PubEx)